Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
International Journal of Medicinal Mushrooms
Facteur d'impact: 1.423 Facteur d'impact sur 5 ans: 1.525 SJR: 0.433 SNIP: 0.661 CiteScore™: 1.38

ISSN Imprimer: 1521-9437
ISSN En ligne: 1940-4344

Volumes:
Volume 21, 2019 Volume 20, 2018 Volume 19, 2017 Volume 18, 2016 Volume 17, 2015 Volume 16, 2014 Volume 15, 2013 Volume 14, 2012 Volume 13, 2011 Volume 12, 2010 Volume 11, 2009 Volume 10, 2008 Volume 9, 2007 Volume 8, 2006 Volume 7, 2005 Volume 6, 2004 Volume 5, 2003 Volume 4, 2002 Volume 3, 2001 Volume 2, 2000 Volume 1, 1999

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v9.i2.20
pages 109-122

Immunomodulation and Antitumor Activity of a Mushroom Product, Proflamin, Isolated from Flammulina velutipes (W. Curt.: Fr.) Singer (Agaricomycetideae)

Hirofumi Maruyama
Japanese Association for Integrative Medicine, Kandakonya-cho, Tokyo, Japan
Tetsuro Ikekawa
Japanese Association of Integrative Medicine (JAIM). Association for Popularization of Integrative Medicine and Treatments (NPO, Japan), Sanshin Building, 3F, 2-15-14 Uchikanda, Chiyoda-ku, Tokyo 101-0047,Japan

RÉSUMÉ

Proflamin (PRF), an antitumor agent, is orally effective against the syngeneic tumor in mice and is a biological response modifier obtained from an edible mushroom. It has been isolated from the mycelia of Flammulina velutipes (W. Curt.: Fr.) Singer and is an acidic glycoprotein containing more than 90% protein and less than 10% carbohydrate; its molecular weight is 13,000 ± 4000. PRF greatly increases the lifespan of mice implanted with the syngeneic tumors, B-16 melanoma and adenocarcinoma 755 and inhibits the growth of solid tumors of Sarcoma 180 (S-180) by so-called "host-mediated" antitumor activities. PRF inhibited the growth of S-180 or L1210 leukemia ascite cells in combination with the S-180 solubilized vaccine or glutaraldehyde and Con A-bound L1210 vaccine and showed strong antitumor activity when a combination therapy was given with surgical treatment in mice bearing Meth-A fibrosarcoma (Meth-A). The combination therapy with cryosurgery and PRF was found to abolish the suppression of tumor immunocompetence at 2 weeks after cryosurgery, and it exhibited no toxic actions either in vitro or in vivo. Oral administration of PRF significantly intensified various immunoresponses in tumor-bearing mice, but it was not very effective against the immunity of healthy (non-tumor-bearing) mice. The effective dose range for immunomodulation was rather wide (1−30 mg/kg), and the optimum dose was supposed to be about 10 mg/kg when administered PO, consecutively. These doses were almost the same as those for the treatment of tumors in the mice mentioned above. A protein-bound polysaccharide, EA6, was also isolated from fruit bodies of F. velutipes. Treatment with EA6 after the surgery remarkably inhibited growth of the rechallenged Meth-A solid tumor, and the effect was mediated by CD4+ T cells. Furthermore, EA6 augmented the humoral immunity, cellular immunity, and IL-2 production against Meth-A tumor antigen after surgery.


Articles with similar content:

Combination Therapy of Transplanted Meth-A Fibrosarcoma in BALB/c Mice with Protein-Bound Polysaccharide EA6 Isolated from Enokitake Mushroom Flammulina velutipes (W.Curt.:Fr.)Singer and Surgical Excision
International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 1&2
Tetsuro Ikekawa, Hirofumi Maruyama
Immunopotentiating Properties of Lentinan (1®3)-b-D-glucan Extracted from Culinary–Medicinal Shiitake Mushroom Lentinus edodes (Berk.) Singer (Agaric
International Journal of Medicinal Mushrooms, Vol.5, 2003, issue 4
Mah-Lee Ng, Ann-Teck Yap
Antitumor Effect of Combination Therapy of Proflamin with Cryosurgery of Meth-A Fibrosarcoma in BALB/c Mice
International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 4
Tetsuro Ikekawa, Hirofumi Maruyama
Pharmacological Studies on Certain Mushrooms from China
International Journal of Medicinal Mushrooms, Vol.3, 2001, issue 4
Vincent Eng Choo Ooi
A Randomized, Placebo-Controlled, Multicenter Study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in Patients with Advanced Lung Cancer
International Journal of Medicinal Mushrooms, Vol.5, 2003, issue 4
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai